This article is cited in 2 scientific papers (total in 2 papers)
Biophotonics
Investigation of changes in the absorption spectrum of modern chlorine-containing medicines for photodynamic therapy and methylene blue as a result of exposure to led emissions with a wavelength of 656 ± 10 nm
Abstract:
Changes in the absorption spectra of aqueous solutions of modern chlorinated photosensitizing drugs for photodynamic therapy “Revixan” (Areal, Russia) and “Chloderm” (Chloderm, Russia) in the range of 600–700 nm depending on the intensity and time of exposure to LED emission with a wavelength of 656 ± 10 nm have been studied. The parameters of the CIE Lab color model of the “Revixan” water solution image before and after LED exposure have been studied. In the range of 400–900 nm, the changes in the absorption spectra of an aqueous solution of methylene blue with different initial concentrations after exposure to LED emission with a wavelength of 656 ± 10 nm and an intensity of 180 ± 20 mW/cm2 have been studied. It has been shown that the effect of LED emission changes the absorption spectra of the studied substances and increases the parameter L (brightness) of the CIE Lab color model for “Revixan”. An increase in the intensity of the LED emission and exposure time causes a decrease in the absorption for “Revixan” and “Chloderm” in the range of 600–700 nm and a shift of the peak of the absorption band lying in this range to the infrared region. The effect of the LED emission on an methylene blue aqueous solution causes a decrease in its absorption in the range of 400–900 nm.
This work was carried out within the framework of the program for improving the competitiveness of ITMO University among the world’s leading research and educational centers for 2013–2020 (“5 in 100” program, grant 08-08).
Citation:
A. V. Belikov, Yu. V. Semyashkina, S. N. Smirnov, A. D. Tavalinskaya, “Investigation of changes in the absorption spectrum of modern chlorine-containing medicines for photodynamic therapy and methylene blue as a result of exposure to led emissions with a wavelength of 656 ± 10 nm”, Optics and Spectroscopy, 128:7 (2020), 972–981; Optics and Spectroscopy, 128:7 (2020), 980–988
\Bibitem{BelSemSmi20}
\by A.~V.~Belikov, Yu.~V.~Semyashkina, S.~N.~Smirnov, A.~D.~Tavalinskaya
\paper Investigation of changes in the absorption spectrum of modern chlorine-containing medicines for photodynamic therapy and methylene blue as a result of exposure to led emissions with a wavelength of 656 $\pm$ 10 nm
\jour Optics and Spectroscopy
\yr 2020
\vol 128
\issue 7
\pages 972--981
\mathnet{http://mi.mathnet.ru/os375}
\crossref{https://doi.org/10.21883/OS.2020.07.49570.55-20}
\elib{https://elibrary.ru/item.asp?id=43870291}
\transl
\jour Optics and Spectroscopy
\yr 2020
\vol 128
\issue 7
\pages 980--988
\crossref{https://doi.org/10.1134/S0030400X20070024}
Linking options:
https://www.mathnet.ru/eng/os375
https://www.mathnet.ru/eng/os/v128/i7/p972
This publication is cited in the following 2 articles:
A. V. Belikov, Y. V. Fyodorova, A. D. Kozlova, S. N. Smirnov, “Laser Delivery and Spectral Study of a Modern Chlorine-Containing Drug for the Treatment of Onychomycosis at Laser Radiation with a Wavelength of 450 nm”, Opt. Spectrosc., 131:10 (2023), 947
A. V. Belikov, S. N. Smirnov, A. D. Tavalinskaya, “Laser delivery and spectral study of a chlorine-containing drug for the treatment of onychomycosis with sequential laser (λ = 2810 nm) and photodynamic (λ = 656 ± 10 nm) impact”, Optics and Spectroscopy, 129:7 (2021), 754–762